Author:
Bian Anning,Ye Xiaoxue,Wang Jing,Zeng Ming,Liu Jiayin,Liu Kang,Ning Song,Cui Yugui,Tang Shaowen,Xu Xueqiang,Yuan Yanggang,Su Zhonglan,Lu Yan,Zhou Jing,Ma Xiang,Yang Guang,Huang Yaoyu,Lv Xiaolin,Wang Ling,Zhao Jing,Wang Xiuqin,Liang Ningxia,Xing Changying,Qin Lianju,Wang Ningning
Abstract
AbstractCalciphylaxis is a rare cutaneous vascular disease with clinical manifestations of intolerable pains, non-healing skin wounds, histologically characterized by calcification, fibrointimal hyperplasia, and thrombosis in microvessels. Currently, there are no approved guidelines for this disease. High prevalence of thrombophilias and hypercoagulable conditions in calciphylaxis patients have been recognized in recent years. Here, we report a case of uremic calciphylaxis patient whom was refractory to conventional treatments and then received a salvage strategyviahuman amnion-derived mesenchymal stem cell (hAMSC) intravenous combined with local application. In order to investigate the therapeutic mechanism of hMASCs from the novel perspective of hypercoagulability, coagulation-related indicators, wound status and quality of life were followed up. Improvement of hypercoagulable condition involving correction of platelet, D-dimer and plasminogen levels, skin regeneration and pain alleviation were revealed after hAMSC administration for one year. We propose that hypercoagulability is the therapeutic target of calciphylaxis patients which can be improved by hAMSC treatment.
Publisher
Cold Spring Harbor Laboratory